Annual Report

Overview

The report describes a year marked by the initiation of Cinclus Pharma's first Phase III study, a strategic licensing and commercialization agreement with Zentiva for Europe, and the inclusion of linaprazan glurate on China's national reimbursement list ahead of a planned 2026 launch. It also presents the company's intended societal contribution through improved treatment for severe erosive reflux disease and alignment with UN Sustainable Development Goal 3 on good health and well-being.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services